Viscoelastic agent for protecting eye tissues

FIELD: medical engineering.

SUBSTANCE: viscoelastic has 1.5-2.5% of methylcellulose with 0.02-0.05% thymolol maleate solution and 0.0005-0.001% benzalconium chloride solution as stabilizer being added.

EFFECT: prolonged action; avoided additional drug therapy application.

 

The invention relates to medicine, in particular to ophthalmology, and can be used for intraocular operations to protect the intraocular tissues from surgical trauma and reduce complications.

Known viscoelastics on the basis of methylcellulose used in ophthalmology at the eye surgeries, such as cataract extraction and phacoemulsification to protect the inner tissues of the eye, especially of the corneal endothelium: "Methocel" (USA), "Occucoat" (France), "Vision" (India), "Visiter" (IRTC "eye microsurgery") (Vaspourakan, Laika. Ophthalmic surgery, 1997, No. 1, p.56-61).

However, the use of even more efficient from viscoelastics - vizitiu, which includes methyl cellulose, dissolved in saline solution with phosphate buffer, has certain disadvantages. In particular, when cataract extraction at least 20% of patients with early postoperative period is complicated by intraocular hypertension resulting from mechanical obstruction of the trabecular network viscous gel, i.e. viscoelastic, and a number of patients in this circumstance contributes to the development of secondary glaucoma in the long term.

We set ourselves the goal of reducing the number of complications when using viscoelastic based on methylcellulose.

To solve the task offer is viscoelastic on the basis of methylcellulose, optionally containing timolol maleate as a stabilizer - benzalkonium chloride is in the following ratio of components,% :

methylcellulose - 1,5-2,5

timolol maleate - 0,02-0,05

benzalkonium chloride - 0,0005-0,001

phosphate buffer solution at physiological rest

Viscoelastic prepared from methyl cellulose, resulting from the polymerization of modified monomers of glucose, which under stirring dissolved in saline, balanced phosphate buffer.

The proposed viscoelastic prepared as follows. Take an accurately weighed sample of timolol maleate 0.035 g and benzalkonium chloride 0.00075 grams, is dissolved in 100 ml of physiological solution containing phosphate buffer (0.05 M solution of potassium phosphate dogsleding and sodium phosphate one-deputizing) and contribute 2.0 g of methylcellulose, which under stirring gradually dissolved over night at room temperature. Finally, 1 ml of viscoelastic contains 0.02 g of methylcellulose, timolol maleate 0.35 mg, benzalkonium chloride 0,0075 mg and 1 ml of saline phosphate buffer. The viscosity of the obtained viscoelastic is 4000 PA/sec, which is determined by viscometric. Ready viscoelastic filtered through a membrane filter, pour into bottles and sterilized by autoclaving (at 0.5 MPa and 110°C for 30 min). Boo is Erny solution creates a pH of 6.8 to 7.2; what is required for optimum performance and stability of timolol maleate, part of the proposed viscoelastic.

The proposed viscoelastic in front of the camera when the cataract extraction surgery in addition to effective protection of the intraocular tissues (endothelium and others) during surgical manipulation provides a significant decrease in postoperative intraocular hypertension due to prolonged, due methylcellulose, actions. As β-blocker, timolol maleate reduces production of aqueous humor, thereby normalizing the intraocular pressure after cataract extraction, if the latter is complicated by postoperative hypertension.

The proposed viscoelastic in front of the camera 2 rabbits (4 eyes) with cataract extraction in the experiment revealed no irritating or toxic effects with careful postoperative biomicroscopy and ophthalmoscopy during the month. The proposed viscoelastic used by introducing it into the anterior chamber of the eye.

Example 1. Patient R., 62 years old, was admitted with a diagnosis of Mature senile cataract of the right eye. Survey data: the acuity of light perception with the correct projection light. Intraocular pressure measured at pneumotonometry of 17 mm Hg Data electroholography: Pthe - 19,0; - 0,30; F - 1,41; KB - 84. Gonioscopy: the anterior chamber angle is open, wide, pigmentation trabeculae insignificant. Objective: the appendages of the eye is not changed. The cornea is transparent. Front camera is of medium depth. Iris subtropica, the pupil is round, its diameter equal to 4 mm Lens diffuse cloudy. More deep superficial environment is not ophthalmoscopically.

Under local instillations and retro-bulbar anesthesia, the patient produced cataract extraction with implantation of posterior chamber intraocular lens and cell proposed viscoelastic. Equipment operation: diamond blade is made of puncture of the cornea 13 hours. Through him in front of the camera introduced a 1% solution mezatona (0.1 ml). After pupil dilation anterior lens capsule opened cystotomy. The corneal incision is continued up to 10 hours. The core of the lens is displayed by sliding. Produced lavage and aspiration of cataract masses. Using a syringe with a curved cannula into the anterior chamber introduced the proposed viscoelastic in the amount of 0.2 ml (containing 2.5% methyl cellulose, 0.05% timolol maleate, 0,001% benzalkonium chloride in isoosmotic phosphate buffer). Then in the capsular bag entered posterior chamber IOL. Her alignment is performed using the hook. The anterior capsule of the crystalline lens in the optical zone of the cut. Front camera washed Phys what astora. On the corneal incision superimposed continuous seam. Under the conjunctiva put 0.5 ml of 0.4% solution of dexasone and 0.5 ml of gentamicin (20 mg). Complications during and after surgery were observed.

The patient was discharged on the 5th day field operations with a slightly irritated eye, normal pressure (14 mm Hg - pneumotonometry) and visual acuity equal to 0.8. Visual inspection of the patient one year after surgery revealed that the visual acuity of the operated eye was kept at the same level of 0.8, the intraocular pressure was equal to 16 mm Hg (pneumotonometry), hydrodynamic parameters were within normal limits.

Example 2. Patient W., 67 years old, was admitted for surgery with an almost Mature cataract in the first eye.

Objective: eyes calm, transparent cornea, anterior chamber, the average depth, pupil round, his reaction to light is incomplete and sluggish. The lens partly cloudy. Details of the fundus not ophthalmoscopically.

Acuity of 0.02 not corrects. IOP on pneumotonometry - 16 mm RT. senior Data electroholography: Pabout- 15,0; - 0,25; F - 0,98; CB - 75. Gonioscopic notes medium-wide angle front camera with slight pigmentation of the trabecular system.

Produced cataract extraction with implantation of posterior chamber intraocular lens and the introduction in the anterior chamber of the eye suggest wescoal the stick. After injection of 0.1 ml of 1% mezatona in the anterior chamber through the paracentesis 13 hours and subsequent expansion of the pupil, anterior chamber was opened cystotomy. Performed corneal incision from 13 to 10 hours. The core of the lens is displayed by sliding. After washing and aspiration lenticular masses in front of the camera entered the proposed viscoelastic in the amount of 0.3 ml (containing 1.5% methylcellulose, 0.02% timolol maleate, 0,0005% benzalkonium chloride in isoosmotic phosphate buffer) and produced by the implantation of a posterior chamber artificial lens with partial excision of the anterior capsule. Front camera rinsed with saline. The corneal incision is sutured with a continuous suture. Upon termination of operations under the conjunctiva of the operated eye put 0.5 ml of gentamicin, and 0.5 ml of 0.4% solution of dexasone.

Complications during and after surgery were noted.

On the 6th day after the operation the patient was discharged from the hospital to outpatient follow-up care by place of residence. Visual acuity of the operated eye at discharge 0,8-0,9; IOP - 12 mm Hg At the control examination the patient after 7 months visual acuity 0,9-1,0; hydrodynamic parameters without pathological changes.

Using the proposed viscoelastic was operated 9 patients (9 eyes) with Mature senile cataract (basic group). For comparison with the world is essential viscoelastic on the basis of methylcellulose - visition operated 15 people (15 eyes) with Mature senile cataract (control group). The compared groups were comparable in age and sex of patients, and the frequency of common comorbidities. All patients and control group in the pre-operative examination was excluded primary glaucoma. Term follow-up of patients after surgery from 6 months to a year. In the main and control groups during surgery complications were observed.

In the early postoperative period in the study group the only complication in one patient was a smear of blood on the iris, which is self-absorbed on the third day. In any case, in the early postoperative period was not marked hypertension, and in the late secondary glaucoma.

In the control group in the 1st case (6,7%) in the early postoperative period was observed hyphema, which was liquidated during the week under the influence of appointed resolving treatment. In addition, in 4 cases (26.7 percent) in the early postoperative period was recorded hypertension (30-45 mm Hg on pneumotonometry), which in 3 patients was cropped local anti-hypertensive therapy and the use of diakarba (inside). In 1 patient (4.5%) in the remote terms after the operation, despite the normalization of intraocular pressure within the Ah upper limit of normal, on the background of regular instillation antihypertensive drugs has led to the development of secondary glaucoma.

Thus, the application of the proposed viscoelastic when cataract extraction, including the use of IOL, significantly reducing hypertension in the early postoperative period, and secondary glaucoma in later.

Viscoelastic to protect the eye tissues containing methylcellulose, phosphate buffer, characterized in that it additionally contains timolol maleate and benzalkonium chloride in the following ratio, wt.%:

The methylcellulose 1.5 to 2.5

Timolol maleate 0,02-0,05

Benzalkonium chloride 0,0005-0,001

Phosphate buffer Else



 

Same patents:

FIELD: medicine, ophthalmology.

SUBSTANCE: the suggested composition includes an antibacterial chemotherapeutic preparation, plant and/or animal phospholipids, sodium chloride, monosodium phosphate, disubstituted sodium phosphate and purified water at certain quantitative ratio of components, weight%. The innovation provides prolonged antiphlogistic action onto inflammatory focus.

EFFECT: higher efficiency of application.

5 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: the suggested composition includes a steroid-free antiphlogistic preparation, plant and/or animal phospholipids, sodium chloride, monosodium phosphate, disubstituted sodium phosphate and purified water at certain quantitative ratio of components, weight%. The innovation provides prolonged antiphlogistic action.

EFFECT: higher efficiency of application.

3 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with medicinal preparations designed as solution and indicated for therapeutic needs. Eye drops contain ciprofloxacin hydrochloride monohydrate being equivalent to 0.3% free foundation, a buffer system that keeps pH within 3.5-5.5 interval, as a conserving agent - benzalconium chloride and a s a stabilizer - the salt of disodium ethylenediamine tetraacetic acid, moreover, their range of osmolality values correspond to 150-450 mM/kg H2O. Eye drops should be obtained by preparing buffer system in which mannitol should be dissolved followed by the salt of disodium ethylenediamine tetraacetic acid, benzalconium chloride, ciprofloxacin hydrochloride. Then one should perform the control for the quality of obtained solution to be then filtered by applying sterilizing elements and packed. This innovation provides treatment of eyes at creating the pressure in an eye and at certain desired osmolality.

EFFECT: higher efficiency of therapy.

4 cl, 1 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: one should introduce 1.0% serotonin adipinate solution intravenously due to infusion once daily for 10-12 d. The method enables to increase visual functions due to decreased tissue hypoxia and normalization of retinal microcirculation, resorption of hemorrhages, reverse development of retinal edema, normalization of functional thrombocytic activity and hemostatic values.

EFFECT: higher efficiency for therapy.

1 ex

FIELD: medicine, in particular ophthalmology.

SUBSTANCE: treatment of ophthalmology diseases by administration in conjunctival sac of patient eye as well as injection of medicine, in particular alkali salt of 5-amino-2,3-dihydro-1,4-phtalasindione is disclosed. Eye drops, eye ointment contain alkali salts of 5-amino-2,3-dihydro-1,4-phtalasindione or mixture thereof, wherein lithium or sodium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phtalasindione is selected as alkali salt, and mixture of above mentioned salt in equal ratio is used as mixture salts of 5-amino-2,3-dihydro-1,4-phtalasindione.

EFFECT: treatment method with improved effectiveness and reduced treatment duration.

16 cl, 6 ex

FIELD: medicine, in particular ophthalmology.

SUBSTANCE: claimed composition contains (mass %): antiviral drug 0.001-5; vegetable and/or animal phospholipids 0.001-2; sodium chloride 0.8-0.9; sodium hydrophosphate 0.001-0.2; sodium dihydrophosphate 0.001-0.2; and balance: distilled water.

EFFECT: composition with prolonged and effective action.

3 ex

FIELD: medicine.

SUBSTANCE: method involves introducing hypotensive means by means of instillations. Eye drops of emoxipin are instilled 20-30 min later twice a day during 4-8 weeks. The treatment course is repeated in 2-3 months.

EFFECT: improved vision function; normalized hemodynamic values.

1 tbl

The invention relates to medicine, namely to ophthalmology, and is intended for the treatment of inflammatory processes in the eyeball

The invention relates to the field of medicine

FIELD: veterinary pharmaceutics.

SUBSTANCE: the present innovation deals with a complex oily polyvitaminic preparation that regulates metabolic processes and decreases the frequency of selenium deficiency manifestation in animal body, poultry, among them, and contains selenium in the form of sodium selenite, retinol acetate as vitamin A and oily solvent in the form of corn germs oil. Thus, cheaper, more active and more stable complex preparation has been obtained that regulates metabolic processes and decreases the frequency of selenium deficiency manifestation in animal and poultry bodies.

EFFECT: higher efficiency of application.

1 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: the suggested ophthalmic composition contains ketothiphen salt, nonionic agent to regulate tonicity in the quantity that total tonicity of composition should correspond to osmolarity of 210-290 mOsm, a conserving agent, not obligatory, either acid or foundation to achieve pH value being slightly acid and water, moreover, if the mentioned conserving agent is not available, the concentration of ketothiphen salt should correspond to 0.01-0.04 weight%, or if the mentioned conserving agent is available, the concentration of ketothiphen salt should correspond to 0.01-0.03 weight%. As ketothiphen salt the suggested composition contains ketothiphen fumarate; tonicity should be controlled with nonionic agent - glycerol.

EFFECT: more prolonged action of the composition suggested.

15 cl, 2 ex

FIELD: medicine, dermatology, pharmacy.

SUBSTANCE: invention relates to an antifungal preparation for external applying. The preparation comprises 2-chloro-4-nitrophenol, polyethylene glycol (PEG-400) and 50% ethyl alcohol. The preparation is used for treatment of epidermophytosis, trichophytosis, fungal eczema, cutaneous candidiasis and other diseases. Invention provides preparing the more effective antifungal preparation based on the domestic raw.

EFFECT: enhanced effectiveness of preparation, valuable medicinal properties.

2 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with medicinal preparations designed as solution and indicated for therapeutic needs. Eye drops contain ciprofloxacin hydrochloride monohydrate being equivalent to 0.3% free foundation, a buffer system that keeps pH within 3.5-5.5 interval, as a conserving agent - benzalconium chloride and a s a stabilizer - the salt of disodium ethylenediamine tetraacetic acid, moreover, their range of osmolality values correspond to 150-450 mM/kg H2O. Eye drops should be obtained by preparing buffer system in which mannitol should be dissolved followed by the salt of disodium ethylenediamine tetraacetic acid, benzalconium chloride, ciprofloxacin hydrochloride. Then one should perform the control for the quality of obtained solution to be then filtered by applying sterilizing elements and packed. This innovation provides treatment of eyes at creating the pressure in an eye and at certain desired osmolality.

EFFECT: higher efficiency of therapy.

4 cl, 1 ex

Acyzol-based agent // 2247558

FIELD: pharmaceutical industry.

SUBSTANCE: invention provides novel nontoxic and highly bioavailable acyzol-based agent characterized by high activity in treatment of skin diseases, in restoration of structural skin processes, suppression of nevus pigmentosis, and flattening of folds.

EFFECT: increased assortment of skin-healing drugs.

7 cl, 4 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with mixing water for injections, conservation agent, metronidasol till complete dissolving at 50-60 C, adding a buffer (NaOH solution) pH 4.5-6.5 at pre-estimated quantity of water, then one should sterilize the obtained medicinal form due to membranous filtration followed by sterile packaging. As a conservation agent one should apply sodium chloride at the quantity of 1.5-2.0 against metronidasol weight, then metronidasol solution should be supplemented with a half-volume of sodium chloride solution, after complete dissolving the obtained solution should be supplemented with the rest quantity of sodium chloride solution. As for membranous filtration it should be carried out by applying a capsule out of polypropylene with hydrophilic membrane of 1.2 mcm. The method provides no crystallization of an active substance during prolonged period of time.

EFFECT: higher therapeutic efficiency.

1 ex, 1 tbl

FIELD: pharmacology, fluorinated quinolone-based drug, in particular ofloxacine for injections.

SUBSTANCE: claimed composition contains therapeutically acceptable amount of ofloxacine and trilon-B, sodium chloride, water for injections as additives.

EFFECT: high therapeutic effectiveness; non-crystallized active agent for a long-time storage.

1 ex

The invention relates to the field of pharmaceutical industry and relates to aqueous solution for parenteral nutrition mammals

The invention relates to new pharmaceutical compositions that contain the basis or agonist of the basis for the treatment of diabetes, slowing of gastric emptying or reduce food intake, and their dosage forms and methods for their introduction

FIELD: pharmacology, fluorinated quinolone-based drug, in particular ofloxacine for injections.

SUBSTANCE: claimed composition contains therapeutically acceptable amount of ofloxacine and trilon-B, sodium chloride, water for injections as additives.

EFFECT: high therapeutic effectiveness; non-crystallized active agent for a long-time storage.

1 ex

Up!